## Correction: Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance

Kristensen LE, Danese S, Yndestad A, et al. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum Dis 2023;82:901-910. doi:10.1136/ ard-2022-223715

In figure 1C of the originally published version of the manuscript, the plotted value for All cause death for the Age  $\geq$ 65 years and Ever smoked group showed the incidence rate (95% Confidence Interval [CI]) (1.81 (1.15, 2.71)) instead of the hazard ratio (HR) vs tumour necrosis factor inhibitors (TNFi (95% CI)) (2.09 (0.85, 5.13)).

This data point has now been corrected to show the HR vs TNFi (95% CI). The corrected figure panel is included below.

## ● Age ≥65 years and Ever smoked С

Age <65 years or Never smoked Tofacitinib (N=420) vs TNFi (N=215) Tofacitinib (N=2491) vs TNFi (N=1236)

3.05 (2.20, 4.12) 0.85 (0.67, 1.06)	1377.5 9425.7
0.85 (0.67, 1.06)	9425.7
2.37 (1.60, 3.39)	1263.6
0.77 (0.60, 0.98)	8774.7
0.86 (0.43, 1.54)	1277.3
0.31 (0.20, 0.45)	8804.5
1.04 (0.55, 1.77)	1253.5
0.44 (0.31, 0.60)	8720.6
1.81 (1.15, 2.71)	1272.4
0.48 (0.34, 0.65)	8774.3
	2.37 (1.60, 3.39) 0.77 (0.60, 0.98) 0.86 (0.43, 1.54) 0.31 (0.20, 0.45) 1.04 (0.55, 1.77) 0.44 (0.31, 0.60) 1.81 (1.15, 2.71) 0.48 (0.34, 0.65)

tofacitinib TNFi



Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work noncommercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/ 4.0/.

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Ann Rheum Dis 2024;83:e11. doi:10.1136/ard-2022-223715corr1

